Danish pharmaceutical company Novo Nordisk wants to keep innovating and finding new cures, according to a comment made by Novo Nordisk's new Chief Schientific Officer Marcus Schindler at a virtual media event in connection with a conference held by the American Diabetes Association.
"What I'm responsible for in my new role is to bring new hypotheses and new ideas for new treatments that address specific unmet medical needs," says Schindler.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.